Straits Times Index
3,176.51 -11.15 (-0.35%) Nikkei
37,068.35 -1,011.35 (-2.66%) Hang Seng
16,224.14 -161.73 (-0.99%) FTSE 100
7,895.85 +18.80 (+0.24%) Bitcoin USD
63,979.54 +2,266.27 (+3.67%) CMC Crypto 200
1,371.97 +59.34 (+4.52%)
ResMed Inc. (RMD)
After hours:
| Previous close | 177.61 |
| Open | 179.15 |
| Bid | 0.00 x 800 |
| Ask | 0.00 x 1000 |
| Day's range | 176.92 - 179.43 |
| 52-week range | 132.24 - 243.52 |
| Volume | |
| Avg. volume | 1,050,198 |
| Market cap | 26.307B |
| Beta (5Y monthly) | 0.67 |
| PE ratio (TTM) | 29.56 |
| EPS (TTM) | 6.05 |
| Earnings date | 25 Apr 2024 |
| Forward dividend & yield | 1.92 (1.07%) |
| Ex-dividend date | 07 Feb 2024 |
| 1y target est | 202.68 |
ZacksResMed (RMD) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
ResMed (RMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
GlobeNewswireResMed to Report Third Quarter Fiscal 2024 Earnings on April 25, 2024
SAN DIEGO, April 04, 2024 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) today announced it plans to release financial and operational results for the third quarter of fiscal year 2024 on Thursday, April 25, 2024, after the New York Stock Exchange closes. Following the release, ResMed management will host a webcast to discuss the results. Other forward-looking and material information may also be discussed during the webcast. Earnings webcast details: • Location:http://investor.resmed.com • Da
Zacks5 Medical Product Stocks to Buy Amid Industry Challenges
Despite the ongoing macro headwinds, recovering demand for medical procedures and cost-cutting initiatives should support the Zacks Medical-Products industry. SYK, RMD, ZBH, PODD and LNTH are well-poised to gain from the favorable factors.
